Staff

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing...

SURVIVORNET LAUNCHES POWERFUL NEW VIDEO SERIES FEATURING WOMEN SHARING PERSONAL STORIES OF THRIVING AFTER SURVIVING BREAST CANCER

'The Breast Cancer Dialogues' Available Now Watch First Two Episodes HERE NEW YORK, Sept. 3, 2025 /PRNewswire/ -- SurvivorNet, the nation's leading...

RealTime eClinical Solutions Launches TrialAlign: Transforming Clinical Research Site Selection and Feasibility with Unbiased Performance Data

SAN ANTONIO, Sept. 3, 2025 /PRNewswire/ -- RealTime eClinical Solutions announces the launch of TrialAlign, a groundbreaking site selection, feasibility,...

error: Content is protected !!